Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

- Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose -


- Primary efficacy endpoint...

Related Keywords

New York ,United States ,United Kingdom ,Copenhagen ,Køavn ,Denmark ,Netherlands ,Massachusetts ,Ireland ,Canada ,American ,Gitte Moos Knudsen ,Doug Drysdale ,Samir Inamdar ,Youtube ,Exchange Commission ,University Of Copenhagen ,Neurobiology Research Unit ,Linkedin ,Drug Administration ,Hospital Harvard Medical School ,Health Canada ,Cybin Inc ,Instagram ,Incremental Response ,Remission Rates ,Second Dose ,Business Wire ,Chief Executive Officer ,Chief Medical Officer ,Study Review ,Maurizio Fava ,Massachusetts General Hospital ,Harvard Medical School ,Chief Neurologist ,Cautionary Notes ,Markets ,